We have invested over £40m over the past five years to support cancer services and improve waiting times, with a focus on urology, colorectal and breast as our most challenged pathways.In response to oncology pressures, we have committed to additional funding for chemotherapy services reaching up to £10m per annum by 2027, with £3m released in 2023-24, £4.6m released in 2024-25 and £6.6m in 2025-26.In addition to this, we have provided 13 mobile MRI and 4 mobile CT scanners to increase activity...